Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Disc Medicine Inc. (IRON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: IRON (3-star) is a STRONG-BUY. BUY since 13 days. Profits (2.69%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
11 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $98.27
Year Target Price $98.27
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 102.56% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.89B USD | Price to earnings Ratio - | 1Y Target Price 98.27 |
Price to earnings Ratio - | 1Y Target Price 98.27 | ||
Volume (30-day avg) - | Beta 2.5 | 52 Weeks Range 30.82 - 68.73 | Updated Date 06/28/2025 |
52 Weeks Range 30.82 - 68.73 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.89 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.25% | Return on Equity (TTM) -23.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1224761277 | Price to Sales(TTM) - |
Enterprise Value 1224761277 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.56 | Shares Outstanding 34634300 | Shares Floating 26710661 |
Shares Outstanding 34634300 | Shares Floating 26710661 | ||
Percent Insiders 10.57 | Percent Institutions 98.94 |
Analyst Ratings
Rating 4.73 | Target Price 98.27 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Disc Medicine Inc.
Company Overview
History and Background
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Founded in 2017, the company has focused on targeting fundamental pathways of iron metabolism to address diseases of erythropoiesis, heme synthesis, and iron overload.
Core Business Areas
- Hematology: Development of therapies for hematologic diseases, including those related to red blood cell disorders and iron metabolism.
- Erythropoiesis: Focus on improving the production of red blood cells in patients with conditions like anemia.
- Heme Synthesis: Developing therapies focused on targeting heme synthesis pathways.
Leadership and Structure
The leadership team includes experienced executives and scientists in drug development and hematology. The company has a board of directors with expertise in biotechnology and finance. Specific names and organizational charts can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- Bitopertin: A GlyT1 inhibitor for erythropoietic porphyrias (EPP) and X-linked protoporphyria (XLP). The target market is patients with EPP and XLP, which are rare genetic disorders. Competitors would be companies developing other treatments for these rare disorders, with limited comparable data currently.
- DISC-0974: An anti-hemojuvelin (HJV) antibody being developed for anemia of inflammation, including myelofibrosis. There are also plans to look at additional clinical indications such as in Diamond-Blackfan anemia and chronic kidney disease.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with a growing focus on precision medicine and targeted therapies. Hematology, in particular, sees significant research and development activity due to the unmet needs of patients with blood disorders.
Positioning
Disc Medicine is positioned as a company developing novel therapies for hematologic diseases, particularly those related to iron metabolism and red blood cell production. The company's competitive advantage lies in its targeted approach to addressing the root causes of these diseases.
Total Addressable Market (TAM)
The TAM for hematologic disease therapies is substantial and expanding with the rise in rare diseases. Given Disc Medicine's focus on rare anemias the TAM would be approximately $2 - $5 billion dollars based on related markets. The company is well positioned to capture a portion of this market with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting specific pathways in hematology
- Experienced leadership team
- Strong intellectual property portfolio
- Focus on rare diseases with unmet medical needs
Weaknesses
- Reliance on clinical trial success
- Limited commercialization experience
- Dependence on funding for research and development
- Product pipeline in early stages
Opportunities
- Expansion of pipeline into additional hematologic diseases
- Partnerships with larger pharmaceutical companies
- Accelerated regulatory pathways for orphan drugs
- Advancements in personalized medicine
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory environment
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- CRSP
- BLUE
- GBT
Competitive Landscape
Disc Medicine competes with established pharmaceutical companies and biotechnology firms developing therapies for hematologic diseases. Its competitive advantage lies in its focus on novel targets and its pipeline of differentiated drug candidates. It must compete against companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Disc Medicine's growth is primarily driven by its clinical development programs. Historical growth is tied to funding rounds and milestone achievements in its clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals of its drug candidates. Analyst estimates vary, but generally reflect positive outlooks if clinical milestones are met.
Recent Initiatives: Recent initiatives include advancing its clinical trials for Bitopertin and DISC-0974 and exploring new indications for its drug candidates.
Summary
Disc Medicine is a clinical-stage biopharmaceutical company with a focus on hematologic diseases. The company's strength lies in its novel drug candidates and experienced leadership team. Its weaknesses include its reliance on clinical trial success and limited commercialization experience. While the company has several opportunities, it faces threats from competitors and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Disc Medicine Inc. website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Disc Medicine Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-08-12 | CEO, President & Director Dr. John D. Quisel Esq., J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 94 | Website https://www.discmedicine.com |
Full time employees 94 | Website https://www.discmedicine.com | ||
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.